A novel high throughput assay to measure plasma neutralizing activity against SARS-CoV2
To date, there is no vaccine and no specific antiviral agent against SARS-CoV-2. Because of hospital saturation, controversial drug efficiency and the risk of medicinal shortage, there is an urgent need for alternative treatment options. Passive (plasmapheresis) and active immunization (vaccine) approaches aim to provide or elicit a protective humoral immune response against SARS-CoV-2. This project aims to develop a high throughput assay to measure the neutralizing activity of COVID-19 patients. It will help characterize the antibody response against SARS-CoV-2, and select the sera with hi...
Development of a high performance COVID-19 immunoassay to assess population-based viral immunity
The current situation of lock-down in many countries creates a strong need for large screening efforts in order to assess the immune status of the population and to advice decision makers on measures to relaunch social and economic activites. Due to the need for serological testing on high numbers of individuals over several months, shortages are predictable and a major threat to society. The present proposal aims at the setup of a diagnostic assay using an immunodetection technique and recombinant viral surface proteins expressed and purified in Luxembourg. This assay will allow Luxembourg...